Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<keyword id="66" type="General" weightage="50" keywordseo="delhi" source="Orion">Delhi</keyword> on Monday reported its second <keyword id="7616951" type="General" weightage="20" keywordseo="monkeypox" source="Orion">monkeypox</keyword> case. A 35-year-old Nigerian man, who was admitted to the LNJP hospital, has tested positive for the infection, a source told IANS. He is the second confirmed case of monkeypox in the city. The foreign national was admitted two days ago to the LNJP hospital which has been designated by the government as the nodal hospital for treatment of the infection. As per the source, the Nigerian man has no recent history of foreign travel. His samples were sent to the <keyword id="6375751" type="General" weightage="80" keywordseo="national-institute-of-virology" source="Orion">National Institute of Virology</keyword> (<keyword id="50971" type="General" weightage="80" keywordseo="niv" source="Orion">NIV</keyword>) in <keyword id="2094" type="General" weightage="80" keywordseo="pune" source="Orion">Pune</keyword>, and the confirmation report reached the hospital on Monday evening. Apart from that, a suspected case of monkeypox has also been admitted to the hospital on Monday. Currently, the hospital has two suspected <keyword id="44392" type="General" weightage="20" keywordseo="cases" source="Orion">cases</keyword> of monkeypox. With two confirmed cases in the national capital, the nationwide tally of monkeypox infection has reached six while one person in Kerala has succumbed to the virus. SEE ALSO : <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/jio-is-fully-ready-for-5g-rollout-in-the-shortest-period-of-time-says-akash-ambani/articleshow/93287582.cms">Jio is fully ready for 5G rollout in the shortest period of time says Akash Ambani</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/indian-markets-may-open-lower-on-fear-of-global-recession/articleshow/93286958.cms">Indian markets may open lower on fear of global recession</a>

Delhi records second monkeypox case, nationwide tally reaches 6

Samples collected from a man with suspected symptoms of <keyword id="7616951" type="General" weightage="100" keywordseo="monkeypox" source="Orion">Monkeypox</keyword> were sent to the <keyword id="6375751" type="General" weightage="50" keywordseo="national-institute-of-virology" source="Orion">National Institute of Virology</keyword> (<keyword id="50971" type="General" weightage="80" keywordseo="niv" source="Orion">NIV</keyword>) <keyword id="2094" type="General" weightage="50" keywordseo="pune" source="Orion">Pune</keyword> on Monday. Five types of samples of the 40-year-old man currently in isolation at <keyword id="177659" type="General" weightage="50" keywordseo="fever-hospital" source="Orion">Fever Hospital</keyword> in <keyword id="6354552" type="General" weightage="50" keywordseo="hyderabad" source="Orion">Hyderabad</keyword> were collected and sent to the lab. The samples include swab from throat, blood, urine, from lesions on skin. According to Fever Hospital superintendent <keyword id="14548303" type="General" weightage="20" keywordseo="dr-k-shankar" source="Orion">Dr K. Shankar</keyword>, the results are likely to be available by Tuesday evening He termed the condition of the man as stable. According to him, the patient is restless and has a running fever. "The lesions on his neck, hands and chest are like lesions from Monkeypox. It may also be chickenpox," Dr Shankar said. The samples were collected after the man was shifted from his home town Kamareddy to Hyderabad on Sunday evening. According to officials he arrived in Kamareddy from Kuwait on July 6. He developed fever on July 20 and later when there were rashes on the body, he approached a private hospital in the town. Suspecting it to be a case of Monkeypox, doctors referred him to Kamareddy District Hospital and from there he was sent in an ambulance to Hyderabad on Sunday. Director of Public Health Dr G. Srinivasa Rao said the man's six close contacts were also identified. Though they have no symptoms, the authorities kept them in isolation as a precautionary measure. The health department is also trying to trace those who came into contact with them during the last few days. The director of public health said that people need not panic over Monkeypox as it is not a fatal disease. He said health minister Harish Rao was monitoring the situation and giving them directions. "We are taking all necessary measures," he said. This is the first suspected case of Monkeypox in Telangana. Neighbouring Andhra Pradesh had reported the first suspected case on July 17. A two-year-old child, who had gone to Dubai with family, was found with skin rashes on return. However, the samples sent to NIV, Pune tested negative for Monkeypox. Telangana's health department is also requesting Gandhi Hospital in Hyderabad to test the samples from the suspected Monkeypox case. The RT-PCR test would be conducted at the government hospital and if the result is positive, the samples will be sent to NIV, Pune for confirmation. However, the samples from the first suspected case were directly sent to NIV. Fever Hospital in Hyderabad recently set up two isolation wards for Monkeypox cases. One isolation ward each was opened for male and female patients. Superintendent of the hospital said they have arranged for 36 beds and the requisite staff, equipment and medicines. Fever Hospital, as the Sir Ronald Ross Institute for Tropical and Communicable Diseases is popularly known, has been declared a nodal centre for treatment of suspected Monkeypox cases. On Sunday, the first suspected case was admitted. The Fever Hospital had also handled the first few suspected cases of Covid-19 in March, 2020. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/finance/news/rupee-appreciates-by-9-paise-to-79-8/-aided-by-crude-oil-prices/articleshow/93106589.cms">Rupee appreciates by 9 paise to 79.8/$ aided by crude oil prices</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/a-girl-born-in-a-poor-tribal-home-could-reach-the-topmost-constitutional-post-says-president-murmu/articleshow/93105884.cms">A girl born in a poor tribal home could reach the topmost constitutional post, says President Murmu</a>

Samples from Telangana's 1st suspected Monkeypox case sent to NIV

<keyword id="9485939" type="General" weightage="100" keywordseo="covaxin" source="Orion">Covaxin</keyword>, India's first indigenous vaccine for Covid-19, has been found to be 77.8 per cent effective, according to the safety and efficacy analysis data from Phase III clinical trials peer reviewed and published in reputed medical journal The Lancet. Hyderabad-based <keyword id="149108" type="General" weightage="20" keywordseo="bharat-biotech" source="Orion">Bharat Biotech</keyword> said the Lancet peer-review confirms the efficacy analysis which demonstrates Covaxin to be effective against Covid-19. The vaccine maker Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2 per cent. A"The efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group," the company said. The efficacy analysis also demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19 "Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects experiencing serious adverse events," it said The efficacy data also shows 63.6 per cent protection against asymptomatic Covid-19, 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta and 70.8 per cent protection against all variants of SARS-CoV-2 virus. Covaxin was developed under a partnership with the Indian Council of Medical Research (ICMR) and the <keyword id="6375751" type="General" weightage="20" keywordseo="national-institute-of-virology" source="Orion">National Institute of Virology</keyword>, with Bharat Biotech receiving the SARS-COV-2 strains through this collaboration. Bharat Biotech had established an ongoing collaboration with ViroVax since 2019, through the Indo-US Vaccine Action Program, to develop and evaluate IMDG (Alhydroxiquim-II), a novel TLR7/8 agonist molecule, which is formulated as part of the adjuvant in Covaxin. The Adjuvant Program of the US National Institute of Allergy and Infectious Diseases (NIAID) has supported ViroVax since 2009. "The peer-review of Covaxin phase III clinical trial data in The Lancet, an authoritative voice in global medicine validates our commitment to data transparency and meeting the stringent peer-review standards of world leading medical journals," said Krishna Ella, CMD of Bharat Biotech. He said the data from their product development and clinical trials have been published in 10 peer-reviewed journals, making Covaxin one of the most highly published Covid-19 vaccines in the world. The phase 3 trial Efficacy and Safety Study involving 25,800 volunteers across 25 sites in India is India's largest ever clinical trial conducted for a Covid-19 vaccine. "I am delighted to see that the phase III efficacy data has also been published in The Lancet, one of the most reputed journals worldwide. This itself speaks high about the strong position of Covaxin amongst other global front-runners Covid-19 vaccines.A The bench to bedside journey of Covaxin in less than 10 months showcases the immense strength of Atmanirbhar Bharat along with the Indian academia and industry in fighting against the odds and carving a niche in the global community," said Balram Bhargava, Director General of the ICMR. Recently, the <keyword id="43588" type="General" weightage="20" keywordseo="world-health-organization" source="Orion">World Health Organization</keyword> granted emergency use listing to Covaxin enabling countries to expedite their regulatory approval to import and administer doses. It has also received emergency use authorizations in several countries with applications in process in more than 50 countries worldwide. Bharat Biotech has partnered with Ocugen to obtain approvals for Covaxin in the US and Canada. With more than 150 million doses manufactured, supplied, and with an excellent safety and efficacy profile, Covaxin is a major contributor to the global fight against the Covid-19 pandemic. The vaccine is currently being evaluated in controlled clinical trials in children 2-18 years of age, with results expected during Q4 2021. Bharat Biotech said it was poised to achieve its goal of an annualized capacity of Aabout 1 billion doses of Covaxin by the end of 2021. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/space/news/nasas-spacex-crew-3-successfully-arrives-at-the-international-space-station/slidelist/87660900.cms">All you need to know about NASA’s SpaceX Crew-3 space flight</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/environment/news/in-pics-the-tamil-nadu-floods-have-sent-1700-people-into-relief-camps/slidelist/87660150.cms">In pics: The Tamil Nadu floods have sent 1,700 people into relief camps</a>

India's Covaxin 77.8% effective for COVID-19, says Lancet Report

<keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword>'s first indigenous vaccine against COVID-19, <keyword id="9485939" type="PERSON" weightage="20" keywordseo="covaxin">Covaxin</keyword>, is safe and generates immune response without any serious side effects, according to the interim results of the phase 2 trials published in The <keyword id="6361830" type="COMPANY" weightage="20" keywordseo="lancet">Lancet</keyword> Infectious Diseases journal. The authors of the study noted that the phase 2 results did not asses the efficacy of the vaccine codenamed BBV152. Developed by <keyword id="149108" type="PERSON" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword> in collaboration with the Indian Council of Medical Research (ICMR) and the <keyword id="6375751" type="COMPANY" weightage="20" keywordseo="national-institute-of-virology">National Institute of Virology</keyword> (NIV), Pune, the vaccine has been granted emergency use authorisation in clinical trial mode by the Indian government. Covaxin had initially raised concerns among experts over its emergency approval by India's drug regulator. The latest study comes a week after Bharat Biotech announced that the vaccine has shown 81 per cent efficacy in the third phase of clinical trials, the results of which are yet to be published. The phase 2 trial to evaluate the immunogenicity and safety of BBV152 vaccine was conducted in healthy adults and adolescents aged 12-65 years at nine hospitals across nine states in India. Two intramuscular doses of vaccine were administered on day 0 and day 28. The primary outcome was assessed in all participants who had received both doses of the vaccine. Safety was assessed in participants who received at least one dose of the vaccine. Between September 5 and 12, last year, 921 potential participants were screened, 380 of whom were enrolled. "We report interim findings of the phase 2 trial on the immunogenicity and safety of BBV152, with the first dose administered on day 0 and the second dose on day 28," the authors of the study said. In the phase 1 trial, published in the same journal last month, BBV152 induced high neutralising antibody responses that remained elevated in all participants three months after the second vaccination. In the phase 2 trial, BBV152 showed better reactogenicity and safety outcomes, and enhanced humoral and cell-mediated immune responses -- two main mechanisms within the adaptive immune system -- compared with the phase 1 trial. Adaptive immunity occurs after exposure to an antigen either from a pathogen or a vaccination. Reactogenicity refers to the property of a vaccine of being able to produce common, adverse reactions, especially excessive <keyword id="1441458" type="DOMAIN" weightage="20" keywordseo="immunological">immunological</keyword> responses and associated signs and symptoms, including fever and sore arm at the injection site. Covaxin is an inactivated vaccine developed by chemically treating novel coronavirus samples to make them incapable of reproduction. This process leaves the viral proteins, including the spike protein of the coronavirus, which it uses to enter the human cells, intact. Given as two doses, three weeks apart, the viral proteins in the vaccine activate the immune system and prepare people for future infections with the actual infectious virus. "The results reported in this study do not permit efficacy assessments. The evaluation of safety outcomes requires extensive phase 3 clinical trials," the authors of the Lancet study said. "We were unable to assess other immune responses in convalescent serum samples due to the low quantity," they said. Even though direct comparisons between the phase 1 and 2 trials cannot be made, the reactogenicity assessments reported in this study were substantially better in the phase 2 trial than the phase 1 trial and other trials with a placebo group, according to the authors. Also, the proportion of participants reporting adverse events in the phase 2 trial were lower than in the phase 1 trial, they noted. "This study enrolled a small number of participants aged 12-18 years and 55-65 years. Follow-on studies are required to establish immunogenicity in children and in those aged 65 years and older," the authors added. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/craftsman-automation-has-fixed-a-price-band-of-14881490-a-share-for-its-150-crore-ipo/articleshow/81408729.cms">Auto components maker Craftsman Automation’s ₹150 crore IPO to hit the capital markets next week — price band fixed at ₹1,488–1,490</a> <a href="https://www.businessinsider.in/india/news/india-is-using-the-quad-alliance-to-get-help-from-the-us-japan-and-australia-to-match-chinas-covid-19-vaccine-push/articleshow/81408044.cms">India is asking the QUAD for money to boost vaccine production and counter China’s moves on the global stage</a> <a href="https://www.businessinsider.in/business/corporates/news/elon-musks-net-worth-has-eroded-60-billion-in-just-two-months-as-teslas-market-cap-falls-35/articleshow/81407453.cms">Elon Musk’s wealth has eroded $60 billion in just two months as Tesla's market cap falls 35%</a>

Covaxin phase two data shows vaccine safe, induces immune response, says Lancet study

<ul class="summary-list"><li>China last week nominated the Wuhan Institute of Virology for a top science award in the country.</li><li>The lab's head, Shi Zhengli, dubbed as China's "Batwoman," separately received an honorable mention from the Chinese Academy of Sciences.</li><li>The nominations came after China's foreign ministry spokesman Zhao Lijian said the lab deserved a Nobel Prize.</li></ul>China has nominated the Wuhan Institute of Virology for the nation's top science award, even as suspicions continue to swirl around whether or not COVID originated in its labs. The Chinese Academy of Sciences on June 18 released the list of nominees for the "Outstanding Science and Technology Achievement Prize," which included the Wuhan Institute of Virology, per a report from local media outlet <a href="https://finance.sina.com.cn/jjxw/2021-06-20/doc-ikqcfnca2046541.shtml">Sina News</a>. The lab was nominated for its "comprehensive and systematic research on the COVID-19 virus." Shi Zhengli, the head of the Wuhan lab dubbed as China's <a href="https://www.reuters.com/article/us-health-coronavirus-who-china-idUSKBN2A309F">"Batwoman,"</a> got an honorable mention as well for her work on "identifying the origin of COVID-19, and creating a model to isolate genes from the virus." The nomination came just a day after China's Foreign Ministry spokesperson Zhao Lijian said the lab <a href="https://www.businessinsider.com/china-says-wuhan-institute-virology-deserves-nobel-prize-2021-6">deserved to win a Nobel Prize for their COVID research</a> instead of facing backlash."The genome sequence of COVID-19 was first identified by Chinese scientists, but that does not mean Wuhan is the source of the coronavirus, nor can it be inferred that the coronavirus was made by Chinese scientists," Zhao said last week at a <a href="https://www.fmprc.gov.cn/mfa_eng/xwfw_665399/s2510_665401/2511_665403/t1884561.shtml">press conference.</a>Shi also <a href="https://www.businessinsider.com/wuhan-virologist-shi-zhengli-denies-covid-19-lab-leak-nyt-2021-6">denied</a> in an <a href="https://www.nytimes.com/2021/06/14/world/asia/china-covid-wuhan-lab-leak.html?action=click&amp;module=Top%20Stories&amp;pgtype=HomepageHomepage">interview with The New York Times</a> published on June 14 that COVID originated from the Wuhan Institute of Virology."How on earth can I offer up evidence for something where there is no evidence?" Shi said during the interview with The Times."I don't know how the world has come to this, constantly pouring filth on an innocent scientist," Shi added.Despite these repeated denials from China, there is still suspicion that <a href="https://www.businessinsider.com/wuhan-lab-leak-animal-spillover-coronavirus-origin-questions-2021-5">COVID was leaked from the Wuhan lab,</a> particularly after a <a href="https://www.wsj.com/articles/intelligence-on-sick-staff-at-wuhan-lab-fuels-debate-on-covid-19-origin-11621796228">Wall Street Journal</a> report last month revealed that three staff members at the lab fell ill more than a month before experts identified and reported the first cases of COVID in the area. President Joe Biden has since <a href="https://www.businessinsider.com/biden-administration-officials-call-probe-coronavirus-origins-2021-5">called for a 90-day investigation into the lab leak theory</a>.

China nominated the Wuhan Institute of Virology for the nation's top science award amid mounting suspicions that COVID was made and leaked from its labs

New Delhi [India], February 4 (ANI): India will see a surge in cancer cases in the coming years which can go upto 20 lakhs per year by 2026, as estimate by <keyword id="40458" type="General" weightage="100" keywordseo="aiims" source="Orion">AIIMS</keyword> based on the data provided by the Indian Council of Medical Research (ICMR). Dr S V S Deo, Professor of Surgical Oncology at AIIMS Delhi, while speaking to stated that India is witnessing a surge in the number of cancer patients. He further stated, "13-14 lakh people are getting affected by the deadly disease each year and the figure could go in excess of 20 lakhs by the year 2026." The AIIMS doctor mentioned that the theme for this year's World Cancer Day, being celebrated on February 4, is 'closing the gap'. He explained that the theme has been chosen keeping in mind the lack of awareness about the myths surrounding cancer and the need to educate people regarding the disease. Deo stated that people have the misconception about Cancer being incurable which is completely dubious. He explained that the disease can be cured if diagnosed on time and this is why an awareness campaign is being run to impart this information to the public. Explaining the details of the campaign, he said, "different activities have been planned to raise awareness. Doctors will be interacting with people and rallies will be taken out to educate and disseminate information." Sharing tips on how to keep cancer at bay, he said that people need to realise the importance of leading a healthy lifestyle and keeping a clean healthy diet. He further explained that processed and packed food items should be avoided as it enhances the risk of cancer. He further said that smoking and consumption of alcohol account for 30 per cent of total cancer cases. Speaking on the rise in gallbladder-related illness, Deo said, "Cases of gallbladder cases in women has been on the rise especially in the north-eastern parts of the country and settlements beside rivers." The doctor said that North-East accounted for the most number of cancer cases related to stomach, gallbladder, neck, head, food pipe etc pertaining to their unhealthy lifestyle and consumption of unhygienic water and food. <keyword id="11889336" type="General" weightage="50" keywordseo="sushma-bhatnagar" source="Orion">Sushma Bhatnagar</keyword>, the head of <keyword id="16351049" type="General" weightage="50" keywordseo="national-cancer-institute-of-india" source="Orion">National Cancer Institute of India</keyword> told ANI, "Cases of genetic cancer in children below the age of 16 has increased in the country." She also stated that a major chunk of cancer cases are a result of air pollution, water pollution and an unhealthy lifestyle. Highlighting the spike in air pollution, the doctor said, "It has caused an increase in the cases of cervical cancer. <keyword id="674224" type="General" weightage="50" keywordseo="delhi-ncr" source="Orion">Delhi NCR</keyword> witnessed 22000 cases of cancer last year of which 50 per cent of cases were treated at the National Cancer Institute, AIIMS." She stated that earlier the majority of cases were recorded in people above the age of 50, but now the younger generation has fallen prey to the deadly disease. The doctor also informed that joint research with IITs is being carried on to develop technology that will help in the treatment of cancer and the negative after-effects of the disease. (ANI)

India's cancer cases will surge to 20 lakh per year by 2026: AIIMS

Blood delivery through drones can soon be expanded to the whole country, a senior official said after the <keyword id="3658" type="General" weightage="80" keywordseo="india" source="Orion">India</keyword>n Council of Medical Research successfully conducted a trial run of blood bag delivery by <keyword id="6354474" type="General" weightage="20" keywordseo="drone" source="Orion">drone</keyword>s under its iDrone initiative on Thursday. The initiative was in continuance with the national mission of expanding the drone ecosystem in India. The 'i-DRONE' was first used by <keyword id="6364396" type="General" weightage="100" keywordseo="icmr" source="Orion">ICMR</keyword> during the COVID-19 pandemic for distributing vaccines to hard-to-reach areas. "Today, we are transporting blood and blood-related products which are supposed to be kept at a low temperature. After the experiment, we found that not only can we maintain the temperature but there was also no damage to the products transported. "We sent another sample through an ambulance and if there are no differences in the samples sent using the two modes then drones will be used all over India," said Dr Rajiv Bahl, the director general of ICMR. He also said that "clarity on challenge mapping and identifying the possible solutions can be achieved by developing indigenous capacities in research and introduction of innovations and technologies in the mainstream". "With digitisation, efficient manufacturing of vaccines and development of a rapid delivery mechanism, India achieved 90 per cent coverage within a year. The boost of technology is an accelerator which is gradually pushing India towards achieving the status of being a developed nation," he added. The trial run as part of a path-breaking validation study has been undertaken for the first time in the country by the collaborative efforts of ICMR, Lady Hardinge Medical College, New Delhi, Government Institute of Medical Sciences, Greater Noida, and Jaypee Institute of Information Technology, Noida. The inaugural trial flight carried 10 units of whole blood samples between the Government Institute of Medical Sciences, Greater Noida, and Lady Hardinge Medical College, New Delhi, in visual line of sight, according to an official statement. Some countries are already using drones to deliver blood products, vaccines, pharmaceuticals, medical supplies, and even organs to remote, rural areas or areas with poor infrastructure. In Ghana, drone delivery of blood -- both as laboratory samples and as emergency blood and blood product delivery -- is now available for thousands of health facilities serving millions of people. In the US, where whole blood and blood products are often sparse in rural areas, drones are more highly regulated and air traffic is more congested, the feasibility of drone delivery of blood and blood products is still being assessed. SEE ALSO: <a href="https://www.businessinsider.in/tech/mobile/news/google-pixel-7a-vs-oneplus-11r-comparison-which-phone-should-you-buy-under-50000/slidelist/100153385.cms">Pixel 7a vs OnePlus 11R – which phone should you buy under ₹50,000</a> <a href="https://www.businessinsider.in/tech/news/pixel-fold-pixel-7a-pixel-tablet-and-everything-announced-at-google-i/o-2023/articleshow/100143082.cms">Pixel Fold, Pixel 7a, Pixel Tablet and everything announced at Google I/O 2023</a> <a href="https://www.businessinsider.in/tech/mobile/news/survey-reveals-three-out-of-four-indians-suffer-from-nomophobia-heres-what-it-means/articleshow/100073985.cms">Survey reveals three out of four Indians suffer from NoMoPhobia: Here’s what it means</a>

Blood delivery by drones across India may soon be reality, says ICMR after successful trial run

(Eds: With file pics) Hyderabad, Two major vaccine makers from Hyderabad, <keyword id="1379126" type="General" weightage="20" keywordseo="Biological-E" source="Orion">Biological E</keyword> Ltd and <keyword id="149108" type="General" weightage="100" keywordseo="bharat-biotech" source="Orion">Bharat Biotech</keyword>, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine <keyword id="11370342" type="General" weightage="80" keywordseo="corbevax" source="Orion">Corbevax</keyword> while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin. Dr Vikram Paradkar, Executive Vice President (Manufacturing), Biological E, said the firm produced about 30 crore doses of Corbevax in total, abiding by the vaccine manufacturing commitment to the Central government. In March '22, Biological E successfully supplied 10 crore doses to the government. "Currently, we have approximately 20 crore (200 million) doses that are fully tested and ready for supply, as and when we receive orders. Additionally, we manufactured 20 crore doses equivalent of the antigen which will help us ramp up the manufacturing of the Corbevax finished product quickly," Paradkar told PTI. The vaccine has been developed by Biological E in collaboration with Texas Children's Hospital Center for Vaccine Development (Texas Children's CVD) and Baylor College of Medicine (Baylor) in Houston, Texas, USA. He further said Biological E can begin with the additional vaccine supplies within eight weeks of future orders and can manufacture and supply approximately 10 crore doses of Corbevax on a monthly basis as per its qualified manufacturing capacity. Bharat Biotech sources said the vaccine maker has more than 50 million doses of Covaxin readily available in vials, and over 200 million doses as drug substance. "Additional production capacity is also available to meet product demand," they said adding fresh stocks of the vaccine are available and ready for supplies. Covaxin, India's indigenous COVID-19 vaccine, was developed in collaboration with the <keyword id="6364555" type="General" weightage="50" keywordseo="indian-council-of-medical-research" source="Orion">Indian Council of Medical Research</keyword> (ICMR) - National Institute of Virology (NIV). Due to lack of product demand, production stoppage of Covaxin was initiated earlier this year and also the 50 million doses in vials are set to expire during early 2023, resulting in losses to the company, sources had earlier said. SEE ALSO: <a href="https://www.businessinsider.in/india/news/rise-in-active-covid-19-cases-in-bihar-no-need-for-panic-says-expert/articleshow/96561025.cms">Rise in active COVID-19 cases in Bihar; no need for panic, says expert</a> <a href="https://www.businessinsider.in/science/health/news/covid-19-nasal-vaccine-bharat-biotechs-incovacc-is-the-first-approved-intranasal-vaccine-in-the-world/slidelist/96542239.cms">All you need to know about the world’s first Covid-19 nasal vaccine - iNCOVACC</a>

Biological E, Bharat Biotech together sitting on stockpile of 250 million COVID vaccine doses

<ul class="summary-list"><li>The Trump administration has cut funding to a non-profit agency conducting research on virus transmission between <keyword id="92255" type="PERSON" weightage="60" keywordseo="Bats">bats</keyword> and humans, according to <a href="https://www.politico.com/news/2020/04/27/trump-cuts-research-bat-human-virus-china-213076">Politico</a>.</li><li>The funding cuts to EcoHealth Alliance, a New York-based organization researching on infectious diseases, came after unfounded rumors linked it to the <keyword id="8671082" type="UNKNOWN" weightage="60" keywordseo="wuhan-institute-of-virology">Wuhan Institute of Virology</keyword>.</li><li>The <keyword id="208994" type="CITY" weightage="60" keywordseo="Wuhan">Wuhan</keyword> Institute of Virology is a Chinese research institute that conspiracy theorists have claimed, without evidence, <a href="https://www.businessinsider.com/wuhan-lab-coronavirus-conspiracy-theories-targeted-by-hackers-2020-4?r=AU&amp;IR=TIR=T">leaked the novel coronavirus to the public</a>.</li><li>EcoHealth Alliance denied sending any of its $3.7 million in government funding to the Wuhan institute. The Wuhan lab <a href="https://www.bloomberg.com/news/articles/2020-04-20/wuhan-virus-lab-denies-any-link-to-first-coronavirus-outbreak">has also denied rumors that it had a role</a> in spreading the <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword>.</li><li>Experts have repeatedly said that the theory that the novel coronavirus was lab-leaked <a href="https://www.npr.org/sections/goatsandsoda/2020/04/23/841729646/virus-researchers-cast-doubt-on-theory-of-coronavirus-lab-accident">is incredibly unlikely</a>, and said the virus most likely jumped from bats to humans.</li><li><a href="https://www.businessinsider.com/?hprecirc-bullet">Visit Business Insider's homepage for more stories</a>.</li></ul>President <keyword id="6354484" type="PERSON" weightage="60" keywordseo="Donald-Trump">Donald Trump</keyword>'s administration abruptly cut funding to a non-profit conducting research on virus transmission between bats and humans, over unfounded rumors linking it to a research institute in Wuhan, <a href="https://www.politico.com/news/2020/04/27/trump-cuts-research-bat-human-virus-china-213076">Politico reported</a>. EcoHealth Alliance, a New York-based infectious-diseases research group, had all its future government funding cut to its five-year-long study on bat-to-human virus transmission, Politico reported.The cut came after rumors groundlessly accused EcoHealth Alliance of sending its $3.7 million grant received from the US government to fund the Wuhan Institute of Virology — the <a href="https://www.businessinsider.com/wuhan-lab-coronavirus-conspiracy-theories-targeted-by-hackers-2020-4?r=AU&amp;IR=TIR=T">Chinese research lab</a> which conspiracy theorists have, without evidence, accused of spreading the novel coronavirus to the public.<div type="image" title="Wuhan Institute of Virology lab" height="788" width="1400" msid="75428308" hostid="261"></div><h2>EcoHealth Alliance denies all charges</h2>The <keyword id="190126" type="ORGANIZATION" weightage="60" keywordseo="National-Institutes-of-Health">National Institutes of Health</keyword> (NIH), the US public health agency who sent the research grant, told EcoHealth Alliance in an email that it also needed to stop spending the rest of its 2020 grant, worth about $370,000."At this time, NIH does not believe that the current project outcomes align with the program goals and agency priorities," an NIH deputy director wrote in a letter to EcoHealth Alliance officials seen by Politico.The director also emailed Peter Daszak, the president of EcoHealth Alliance, days before funds were frozen, asking for a list of all Chinese links to the group's study.EcoHealth Alliance said in a statement that it was planning to speak with the NIH "to understand the rationale behind their decision." "For the past 20 years our organization has been investigating the sources of emerging diseases such as COVID-19," the group said, according to Politico. "We work in the United States and in over 25 countries with institutions that have been pre-approved by federal funding agencies to do scientific research critical to preventing pandemics."According to Politico, Daszak told the NIH that "no funds from [the grant] have been sent to the Wuhan Institute of Virology, nor has any contract been signed."The facility has received over $3.7 million in research funding between 2014 and 2019, and has published over 20 scientific papers since 2015 on how coronaviruses spread through bats, according to the report.According to <a href="https://www.snopes.com/fact-check/obama-admin-wuhan-lab-grant/">Snopes</a>, a portion of the $3.7 million in research funding from the NIH to EcoHealth Alliance helped fund research at the Wuhan Institute, though it is unclear how much of the funding or to what capacity the money was used.A reporter from the <a href="https://www.newsmax.com/politics/virology-pandemic-covid-19-funding/2020/04/18/id/963512/">conservative outlet Newsmax</a> also asked about US funding to the Wuhan institute at an April 17 White House press briefing, though she did not mention EcoHealth Alliance by name. "We will end that grant very quickly," Trump told the reporter.The NIH and EcoHealth Alliance did not immediately respond to Business Insider's inquiry about the funding cuts.<div type="image" title="wuhan wet market" height="1000" width="2000" msid="75428314" hostid="261"></div><h2>The Wuhan lab rumors and why experts are shutting it down</h2>The Wuhan Virology Institute, which conducts high-level research on dangerous pathogens, is located about eight miles from the Wuhan wet market found to be the most likely starting point for the coronavirus outbreak.The agency has been the <a href="https://www.scmp.com/news/china/science/article/3080868/coronavirus-wuhan-lab-conspiracy-theory-will-not-go-away">target of unfounded conspiracy theories</a> claiming that it accidentally leaked the virus out into the public. The lab <a href="https://www.bloomberg.com/news/articles/2020-04-20/wuhan-virus-lab-denies-any-link-to-first-coronavirus-outbreak">has denied any role</a> in spreading the new coronavirus, though the Trump administration <a href="https://www.theguardian.com/world/2020/apr/15/trump-us-coronavirus-theory-china">has brought attention to the conspiracy theory</a> in recent weeks.Earlier this month, a set of State Department cables <a href="https://www.washingtonpost.com/opinions/2020/04/14/state-department-cables-warned-safety-issues-wuhan-lab-studying-bat-coronaviruses/">leaked to The Washington Post</a> warned of safety issues at the Wuhan lab, thrusting rumors of a potential lab accident into the spotlight.But virus researchers have said that the <a href="https://www.npr.org/sections/goatsandsoda/2020/04/23/841729646/virus-researchers-cast-doubt-on-theory-of-coronavirus-lab-accident">idea the virus was somehow released from the Wuhan lab is incredibly unlikely</a>, and have repeatedly stressed that <a href="https://www.businessinsider.com/wuhan-coronavirus-sars-bats-animals-to-humans-2020-1">the virus most likely jumped from bats to humans</a>.<div type="image" title="coronavirus mask" height="1378" width="2000" msid="75428317" hostid="261"></div>The coronavirus is a zoonotic disease, meaning it <a href="https://www.businessinsider.com/wuhan-coronavirus-many-other-disease-outbreaks-to-come-2020-1">jumps from animals to humans</a>. It also shares similarities with other coronavirus outbreaks, like SARS, which was determined to have likely jumped from bats to civets to people.In the past 45 years, <a href="https://www.businessinsider.com/wuhan-coronavirus-sars-bats-animals-to-humans-2020-1">at least three other pandemics have been traced back to bats</a>, including Ebola, Middle Eastern respiratory syndrome (MERS), and the Nipah virus.Despite the lack of evidence supporting the lab-leak theory, experts have had to repeatedly shut down the rumors.A spokesperson for the World Health Organization (WHO) <a href="https://www.reuters.com/article/uk-health-coronavirus-who-virus/coronavirus-very-likely-of-animal-origin-no-sign-of-lab-manipulation-who-idUSKCN223180">poured cold water on the theory last week</a>, stating that the new coronavirus was "likely" of animal origin."All available evidence suggests the virus has an animal origin and is not manipulated or constructed in a lab or somewhere else," WHO spokeswoman Fadela Chaib <a href="https://www.reuters.com/article/uk-health-coronavirus-who-virus/coronavirus-very-likely-of-animal-origin-no-sign-of-lab-manipulation-who-idUSKCN223180">told a news briefing</a>.Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, <a href="https://www.businessinsider.com/fauci-throws-cold-water-conspiracy-theory-coronavirus-escaped-chinese-lab-2020-4">also downplayed the theory</a> last week, telling a White House press briefing that the virus mutations seemed consistent with the premise that the disease jumped from bats to humans. Last week, the Wuhan Institute of Virology <a href="https://www.businessinsider.com/wuhan-lab-coronavirus-conspiracy-theories-targeted-by-hackers-2020-4?r=AU&amp;IR=TIR=T">was targeted by hackers</a>. The WHO, Bill &amp; Melinda Gates Foundation, and the US Centers for Disease Control and Prevention were also targeted.Read the original article on <a href="https://www.businessinsider.com/trump-cut-research-funds-bat-virus-conspiracy-theories-politico-2020-4">Business Insider</a>

You Searched For "icmr national institute of virology" and got 9 results

Delhi records second monkeypox case, nationwide tally reaches 6

IANS

Samples from Telangana's 1st suspected Monkeypox case sent to NIV

IANS

India's Covaxin 77.8% effective for COVID-19, says Lancet Report

IANS

Covaxin phase two data shows vaccine safe, induces immune response, says Lancet study

PTI

China nominated the Wuhan Institute of Virology for the nation's top science award amid mounting suspicions that COVID was made and leaked from its labs

Cheryl Teh

India's cancer cases will surge to 20 lakh per year by 2026: AIIMS

ANI

Blood delivery by drones across India may soon be reality, says ICMR after successful trial run

PTI

Biological E, Bharat Biotech together sitting on stockpile of 250 million COVID vaccine doses

PTI

Trump cut funding for a group researching bat-to-human virus transmissions after unfounded conspiracy theories linked it to a Wuhan lab, report says

Rosie Perper

Popular Keywords

Buying Guides